title: Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
abstract: BACKGROUND
  This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.
  
  
  METHODS
  Patients (1,638) were enrolled in CCG 1961 from November 1996 to May 2002. Weight was measured as BMI percent (%), specific for age and gender, and defined as 100 x ln(BMI/median BMI).
  
  
  RESULTS
  By the end of treatment, 23% of children were obese (BMI >or=95%), compared with 14% at diagnosis. Children who received post-induction intensified therapy (arms C, D, SER with Doxorubicin or Idarubicin) had higher gastrointestinal toxicities and lower BMI% from consolidation through interim maintenance 1. BMI% then increased for all arms between delayed intensification and maintenance 1 or 2. Children who were of Black or Hispanic race, obese at diagnosis, or who had grade 3 or 4 pancreatitis/glucose toxicities during induction had higher BMI% throughout treatment. Children were more likely to be obese at the end of the study if they were aged 5-9 years at diagnosis or female gender. Cranial radiation was not a predictor of obesity.
  
  
  CONCLUSIONS
  Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation. The beginning of maintenance therapy may be the best time to intervene with nutritional and behavioral interventions, particularly for children who are obese or aged 5-9 years at diagnosis, female, Black or Hispanic, or those with metabolic toxicities during induction.
authors.affiliation: Children's Cancer and Blood Disorder Center, South Carolina Cancer Center, Columbia, South Carolina, USA.
authors.forename: Janice S
authors.initials: JS
authors.lastname: Withycombe
authors.forename: Janice E
authors.initials: JE
authors.lastname: Post-White
authors.forename: Jane L
authors.initials: JL
authors.lastname: Meza
authors.forename: Ria G
authors.initials: RG
authors.lastname: Hawks
authors.forename: Lynette M
authors.initials: LM
authors.lastname: Smith
authors.forename: Nancy
authors.initials: N
authors.lastname: Sacks
authors.forename: Nita L
authors.initials: NL
authors.lastname: Seibel
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D016371:Cranial Irradiation; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005006:Ethnicity; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D018149:Glucose Intolerance / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009765:Obesity / Q000453:epidemiology / Q000209:etiology; D010195:Pancreatitis / Q000139:chemically induced / Q000453:epidemiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012306:Risk; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D015430:Weight Gain; D015431:Weight Loss; D055815:Young Adult
chemical_list: D003561:Cytarabine; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
references.citation: Eur J Clin Nutr. 2005 Mar;59(3):419-25
references.pmid: 15674315
references.citation: Arch Dis Child. 2003 Sep;88(9):748-52
references.pmid: 12937090
references.citation: Biostatistics. 2000 Jun;1(2):141-56
references.pmid: 12933516
references.citation: Pediatrics. 2003 Aug;112(2):424-30
references.pmid: 12897303
references.citation: Int J Obes Relat Metab Disord. 2003 Oct;27(10):1141-51
references.pmid: 14513062
references.citation: Hum Mutat. 2003 Jun;21(6):557-68
references.pmid: 12754700
references.citation: J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26
references.pmid: 15087948
references.citation: Health Promot Pract. 2008 Jul;9(3):305-12
references.pmid: 16803930
references.citation: Pediatr Res. 1995 Jul;38(1):86-90
references.pmid: 7478803
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5
references.pmid: 11502805
references.citation: Arch Dis Child. 1994 Aug;71(2):147-9
references.pmid: 7944537
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1183-9
references.pmid: 17401007
references.citation: J Pediatr Oncol Nurs. 2006 May-Jun;23(3):135-42
references.pmid: 16624889
references.citation: Cancer. 2005 Apr 15;103(8):1730-9
references.pmid: 15761876
references.citation: Pediatr Blood Cancer. 2005 Dec;45(7):881-91
references.pmid: 16035086
references.citation: Am J Clin Nutr. 2006 Jan;83(1):70-4
references.pmid: 16400052
references.citation: Blood. 2008 Mar 1;111(5):2548-55
references.pmid: 18039957
references.citation: Med Pediatr Oncol. 2000 Aug;35(2):91-5
references.pmid: 10918229
references.citation: Stat Med. 1997 Aug 30;16(16):1859-71
references.pmid: 9280038
references.citation: Int J Cancer Suppl. 1998;11:81-4
references.pmid: 9876486
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1359-65
references.pmid: 12663727
references.citation: Cancer. 2005 Apr 15;103(8):1725-9
references.pmid: 15754333
references.citation: J Pediatr. 1995 Jul;127(1):63-7
references.pmid: 7608813
references.citation: Pediatr Hematol Oncol. 2000 Apr-May;17(3):231-7
references.pmid: 10779989
references.citation: J Clin Oncol. 2007 May 20;25(15):2063-9
references.pmid: 17513811
references.citation: Cancer. 2007 Nov 15;110(10):2313-20
references.pmid: 17896787
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2953-60
references.pmid: 12885815
references.citation: Psychooncology. 2007 May;16(5):448-57
references.pmid: 16915562